AI Article Synopsis

  • Oclacitinib and ciclosporin are immunomodulators used to treat canine atopic dermatitis, with oclacitinib providing rapid relief similar to prednisolone, which is used initially with ciclosporin to enhance its effectiveness.!* -
  • In a study with 16 beagles divided into two groups, dogs received either oclacitinib alone or oclacitinib with ciclosporin for three weeks, with daily monitoring for adverse effects and regular blood tests to assess health.!* -
  • The results showed that both treatments were well tolerated overall, with only minor issues like diarrhea and transient appetite loss noted, indicating that using both drugs together doesn’t increase side effects compared to using o

Article Abstract

Background: Ciclosporin and oclacitinib are immunomodulators approved for the treatment of canine atopic dermatitis. The administration of a short course of prednisolone at the beginning of ciclosporin therapy hastens the efficacy of this drug; oclacitinib has a rapid antipruritic effect similar to that of prednisolone.

Objectives: To evaluate the oral tolerance of oclacitinib and ciclosporin given concurrently for three weeks.

Animals: Two groups of eight beagles.

Methods: Dogs were randomized to receive oclacitinib alone (0.4-0.6 mg/kg twice daily for 14 days then once daily for seven days) or in combination with ciclosporin (5 mg/kg once daily) for three weeks. They were examined every day and adverse events were recorded. Blood samples were collected during the acclimatization phase, weekly during treatment and at the end of the study for haematology, clinical chemistry and coagulation evaluation.

Results: There were no abnormal clinical observations following treatment with oclacitinib given alone or concomitantly with ciclosporin, with the exception of diarrhoea in two dogs receiving both drugs. Three dogs from each group experienced transient inappetence; three dogs treated with oclacitinib had mild weight loss. Clinical pathology parameters remained within the reference range for beagle dogs at that facility.

Conclusions And Clinical Importance: The concomitant administration of ciclosporin and oclacitinib for three weeks to beagles was well tolerated and was not associated with an increase in the number of adverse events or laboratory abnormalities beyond those associated with oclacitinib given alone.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737300PMC
http://dx.doi.org/10.1111/vde.12278DOI Listing

Publication Analysis

Top Keywords

ciclosporin oclacitinib
12
three weeks
12
oclacitinib
9
dogs treated
8
concomitantly ciclosporin
8
oclacitinib three
8
mg/kg daily
8
daily days
8
adverse events
8
three dogs
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!